Target
Bruton's tyrosine kinase (BTK)
17 abstracts
Abstract
Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.Org: The University of Texas MD Anderson Cancer Center, Maria Skłodowska-Curie National Research Institute of Oncology, General University Hospital in Prague, Charles University Hospital and Faculty of Medicine, Wrocław Medical University,
Abstract
Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL).Org: Mayo Clinic-Florida, MD Anderson Cancer Center Madrid, Curis Inc,
Abstract
Real world incidence, prevention, and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax in the inpatient and outpatient settings.Org: St. Luke's Roosevelt,
Abstract
Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL).Org: Mayo Clinic, Stanford University Medical Center, Stanford, CA,
Abstract
An open label, single arm, multicenter phase II study of the efficacy and safety of LP-168 monotherapy for relapsed or refractory mantle cell lymphoma.Org: Hubei Cancer Hosipital, Meizhou People’s Hospital,
Abstract
Efficacy outcomes of treatments for double exposed chronic lymphocytic leukemia/small lymphocytic lymphoma: A systematic literature review.Org: Clinical and Administrative Pharmacy, Health Economics and Health Services Research,
Abstract
Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).Org: Alliance Statistics and Data Management Center, Alliance Protocol Operations Office, Illinois CancerCare, Mayo Clinic, Trinity Health Saint Joseph Mercy Hospital,
Abstract
Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL.Org: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital,
Abstract
BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.Org: Istanbul Medipol University Medical Faculty, International School of Medicine, Merck & Co., Inc., Rahway, NJ, Maria Sklodowska-Curie National Institute of Oncology,
Abstract
Association of pharmacist interventions with adherence upon targeted anticancer oral therapy initiation.Org: VA Salt Lake City Health Care, AbbVie Inc., North Chicago, IL, Hunstman Cancer Institute at the University of Utah,
Abstract
Utility of pharmacogenomic testing in predicting intolerance to BTK inhibitors.Org: Duke Cancer Institute, Durham, NC, Durham VA Medical Center, VA National Precision Oncology Program, VA National Oncology Program Office,
Abstract
Real-world outcomes by race in patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Final analysis results from the informCLL registry.Org: Mount Sinai Comprehensive Cancer Center, Miami Beach, FL, Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, Lymphoma Research Foundation, New York, NY, Janssen, Horsham, PA, Janssen Scientific Affairs, LLC, Horsham, PA,
Abstract
A study of frontline therapy in adults >80 years with chronic lymphocytic leukemia (CLL).Org: Mayo Clinic, Division of Clinical Trials and Biostatistics, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Laboratory and Oncology, Mayo Clinic, Rochester, MN, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN,
Abstract
Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.Org: Department of Neurosurgery, Peking Union Medical College Hospital, Beijing, China, Osaka International Cancer Institute, Osaka, Japan, Department of Neurosurgery and Neuro-Oncology, National Cancer Center Research Institute, Tokyo, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Kyorin University Faculty of Medicine,
Abstract
Safety of concurrent use of radiotherapy for second primary malignancy (SPM) in patients with chronic lymphocytic leukemia (CLL) receiving novel agent therapy.Org: Mayo Clinic, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Division of Clinical Trials and Biostatistics,
Abstract
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.Org: Institute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italy, Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital, Brno, Czech Republic, Institut Bergonié, Bordeaux, France, Institut Catala d'Oncologia (ICO) Hospital Duran I Reynals, Hospital, Barcelona, Spain, Peking University Cancer Hospital & Institute, Beijing, China,
Abstract
Cardiovascular adverse events associated with second generation Bruton tyrosine kinase inhibitor therapy: A systematic review and meta-analysis.Org: Mount Sinai Hospital, University of Louisville, UPMC Harrisburg,